Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016', provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects
- The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Leishmaniasis (Kala-Azar) Overview 10
Therapeutics Development 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Leishmaniasis (Kala-Azar) - Products under Development by Companies 19
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 20
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 21
Advinus Therapeutics Ltd. 21
Anacor Pharmaceuticals, Inc. 22
BioLingus AG 23
Dafra Pharma International Ltd. 24
iCo Therapeutics Inc. 25
ManRos Therapeutics 26
Matinas BioPharma Holdings, Inc. 27
Mologen AG 28
Nanomerics Ltd 29
Takeda Pharmaceutical Company Limited 30
Zydus Cadila Healthcare Limited 31
Leishmaniasis (Kala-Azar) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
18-MC - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
amphotericin B - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
amphotericin B - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
amphotericin B - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
amphotericin B - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CDRI-99/288 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
corifungin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Indotecan hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
interferon gamma - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KVH-14 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
leishmaniasis vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
leishmaniasis vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
leishmaniasis vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
leishmaniasis vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MGN-1331 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NPC-1161B - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Oleylphosphocholine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
P-MAPA - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Peptides for Infectious Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Polysaccharide for Oncology, Infectious Disease and Allergy - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
S-010269 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecule for Leishmaniasis - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule for Leishmaniasis - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Visceral Leishmaniasis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules for Infectious Diseases - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Leishmaniasis - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules for Leishmaniasis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Leishmaniasis - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Protozoal Infections - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for Visceral Leishmaniasis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Visceral Leishmaniasis - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small molecules to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Synthetic Peptides for Infectious Disease - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
visceral leishmaniasis vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 87
Leishmaniasis (Kala-Azar) - Dormant Projects 91
Leishmaniasis (Kala-Azar) - Discontinued Products 93
Leishmaniasis (Kala-Azar) - Product Development Milestones 94
Featured News & Press Releases 94
Mar 22, 2016: Profounda launches Impavido (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States 94
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 94
Sep 28, 2015: Knight Profounda U.S. Partner for Impavido 95
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 95
Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 95
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 96
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 97
Nov 11, 2013: Paladin Announces Extension of the Impavido® PDUFA Date by Three Months 97
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 98
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 98
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2016 11
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H1 2016 21
Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 22
Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H1 2016 23
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H1 2016 24
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2016 25
Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H1 2016 26
Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 27
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2016 28
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2016 29
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 30
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Stage and Target, H1 2016 34
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 40
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H1 2016 87
Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2016 91
Leishmaniasis (Kala-Azar) - Dormant Projects (Contd..1), H1 2016 92
Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2016 93